2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Brève description

The aim of this ESC guideline is to help health professionals manage people with heart failure (HF) according to the best available evidence. Fortunately, we now have a wealth of clinical trials to help us select the best management to improve the outcomes for people with HF; for many, it is now both preventable and treatable. This guideline provides practical, evidence-based recommendations. The format of the previous 2016 ESC HF Guidelines was revised to make each phenotype of HF stand alone in terms of its diagnosis and management. The therapy recommendations mention the treatment effect supported by the class and level of evidence and are presented in tables. In this guideline, we have decided to focus on the diagnosis and treatment of HF, not on its prevention. The 2023 Focused Update of these Guidelines is available here: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Focused-Update-on-Heart-Failure-Guidelines

Groupe cible

Médecins, Infirmiers/infirmières, Sages-femmes, Pharmaciens/pharmaciennes

Spécialité médicale

Médecine interne générale, Endocrinologie/diabétologie, Gynécologie et obstétrique, Cardiologie, Oncologie médicale, Néphrologie, Médecine pharmaceutique, Médecine physique et réadaptation, Pneumologie, Chirurgie thoracique

Catégorie du guide

Diagnostic, Traitement, Prévention, Réadaptation, Evaluation des effets thérapeutiques, Evaluation, Gestion/management, Dépistage

Groupe cible de patients

Classe d'âge: Adultes
Sexe: Masculin, Féminin

Origine

Repris

Domaine d'application

National, Européen, International

Secteur

Les deux/intersectoriel

Langue originale

Anglais

Publié en

2021